KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Restructuring Costs (2016 - 2025)

Eli Lilly (LLY) has disclosed Restructuring Costs for 17 consecutive years, with $84.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Restructuring Costs fell 75.58% year-over-year to $84.1 million, compared with a TTM value of $484.0 million through Dec 2025, down 43.79%, and an annual FY2025 reading of $484.0 million, down 43.79% over the prior year.
  • Restructuring Costs was $84.1 million for Q4 2025 at Eli Lilly, down from $364.9 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $435.0 million in Q2 2024 and bottomed at $35.0 million in Q1 2025.
  • Average Restructuring Costs over 5 years is $179.4 million, with a median of $104.5 million recorded in 2021.
  • The sharpest move saw Restructuring Costs soared 447.18% in 2021, then tumbled 75.58% in 2025.
  • Year by year, Restructuring Costs stood at $104.5 million in 2021, then tumbled by 63.54% to $38.1 million in 2022, then soared by 78.48% to $68.0 million in 2023, then soared by 406.47% to $344.4 million in 2024, then crashed by 75.58% to $84.1 million in 2025.
  • Business Quant data shows Restructuring Costs for LLY at $84.1 million in Q4 2025, $364.9 million in Q3 2025, and $35.0 million in Q1 2025.